Trial · NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457, Phase 3, Recruiting, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis. Trials, record NCT06632457. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06632457
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT number
- NCT06632457
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,590 participants, estimated
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Metabolic Dysfunction Associated Steatohepatitis
- Interventions
- Survodutide, Placebo matching survodutide
- First posted
- 2024-10-09
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH | up to 4.5 years. | MELD = model of end-stage liver disease CSPH = Clinically significant portal hypertension |
| Secondary | Key secondary endpoint: Absolute change from baseline in enhanced liver fibrosis (ELF) score | At baseline and at Week 76. | |
| Secondary | Key secondary endpoint: Percentage change from baseline in body weight | At baseline and at Week 76. | |
| Secondary | Key secondary endpoint: Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c) (%) in participants with type 2 diabetes mellitus (T2DM) at baseline | At baseline and at Week 76. | |
| Secondary | Key secondary endpoint: Absolute change from baseline in liver stiffness (kPa) in FibroScan® vibration-controlled transient elastography (VCTE) | At baseline and at Week 76. | |
| Secondary | Percentage change from baseline in liver stiffness in FibroScan® VCTE | At baseline and at Week 76. | |
| Secondary | Time to first occurrence of progression to CSPH | up to 4.5 years. | |
| Secondary | Time to first occurrence of any of the hepatic decompensation events (ascites, HE, or portal hypertension-related upper GI bleeding), or worsening of MELD score to ≥15 | up to 4.5 years. | |
| Secondary | Occurrence of all-cause hospitalisation (first and recurrent) | up to 4.5 years. | |
| Secondary | Time to first occurrence of any of the adjudicated components of the composite endpoint 5-point major adverse cardiac event (5P-MACE) | up to 4.5 years. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06632457
GET https://conductscience.org/api/trials/v1/NCT06632457/registered